Ian Finkelstein
YOU?
Author Swipe
View article: Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence
Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence Open
Background The discovery of calcitonin gene-related peptide (CGRP) as a key player in migraine pathophysiology has revolutionized the approach to preventive treatment. Atogepant, an oral small-molecule CGRP receptor antagonist, has shown p…
View article: OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study – CORRIGENDUM
OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study – CORRIGENDUM Open
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.
View article: 2606 PREDICT: PREEMPT fixed-dose, fixed-site and follow the pain
2606 PREDICT: PREEMPT fixed-dose, fixed-site and follow the pain Open
Objective Analyse the real-world effectiveness and safety of 155U, 156–195U and 195U onabotulinumtoxinA in patients with chronic migraine (CM) from the PREDICT study. Methods PREDICT (NCT02502123) was a Canadian 2-year, prospective, observ…
View article: CJN volume 50 issue 3 Cover and Front matter
CJN volume 50 issue 3 Cover and Front matter Open
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
View article: 2213 Impact of pandemic on Botox treatment and treatment effect in patients with chronic migraine
2213 Impact of pandemic on Botox treatment and treatment effect in patients with chronic migraine Open
Objectives We studied the impact of the pandemic on Botox treatment and treatment effect in patients with chronic migraine at 1.5 years into the pandemic, in headache clinics in different countries. Methods We carried out a multicentre sur…
View article: CJN volume 49 issue 4 Cover and Front matter
CJN volume 49 issue 4 Cover and Front matter Open
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
View article: OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study
OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study Open
Background: PREDICT was a Canadian, multicenter, prospective, observational study in adults naïve to onabotulinumtoxinA treatment for chronic migraine (CM). We descriptively assess health resource utilization, work productivity, and acute …
View article: OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study
OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study Open
Background: The PREDICT study assessed real-world, long-term health-related quality of life in adults with chronic migraine (CM) receiving onabotulinumtoxinA. Methods: Canadian, multicenter, prospective, observational study in adults naïve…
View article: P.011 OnabotulinumtoxinA, quality of life, health resource utilization, and work productivity in chronic migraine: interim results from PREDICT
P.011 OnabotulinumtoxinA, quality of life, health resource utilization, and work productivity in chronic migraine: interim results from PREDICT Open
Background: We assessed long-term health-related quality of life (HRQoL) and functioning in adults receiving onabotulinumtoxinA for CM. Methods: Interim analysis of multicentre, prospective, observational study in adults naïve to botulinum…